All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for ASSOCIATION OF ACCESSIBLE MEDICINES · Trade Association

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 8

S 1040
Drug Competition Enhancement Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
HR 3269
ETHIC Act
S 43
Skinny Labels, Big Savings Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1262
Mikaela Naylon Give Kids a Chance Act

Lobbying activity 3

Medicare/Medicaid

Issues related to generic medicines.

Health Issues

Issues related to generic and biosimilar medications.

Pharmacy

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.